A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Lenvatinib (Primary)
  • Indications Thyroid cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms SELECT
  • Sponsors Eisai Inc
  • Most Recent Events

    • 12 Sep 2017 Results (n=261) assessing effect of treatment interruption duration on efficacy presented at the 42nd European Society for Medical Oncology Congress
    • 31 Aug 2017 According to an Eisai Inc media release, the company will present the new clinical data from this trial at European Society of Medical Oncology (ESMO) 2017.
    • 28 Aug 2017 According to an Eisai Inc Media Release, Marcia Brose is lead author of the study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top